APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharma Ophthalmic

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pharma Ophthalmic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025193 pages

Choose your research edition.

Industry ResearchPharma Ophthalmic Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharma Ophthalmic Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Pharma Ophthalmic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharma Ophthalmic Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharma Ophthalmic Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pharma Ophthalmic market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pharma Ophthalmic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pharma Ophthalmic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pharma Ophthalmic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pharma Ophthalmic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pharma Ophthalmic include Akorn, Allergan, Regeneron, Senju, Valeant, Bayer, Santen, Pfizer and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pharma Ophthalmic market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharma Ophthalmic and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharma Ophthalmic sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pharma Ophthalmic market size, projected growth trends, production technologies, key applications, and end-use industries.

Pharma Ophthalmic Segment by Company

Akorn

Allergan

Regeneron

Senju

Valeant

Bayer

Santen

Pfizer

Roche

Novartis

Pharma Ophthalmic Segment by Type

Retinal disorders drugs

Glaucoma drugs

Other ophthalmic drugs

Allergic, inflammatory and infective drugs

Dry eye drugs

Pharma Ophthalmic Segment by Application

Dry eye syndrome

Other ophthalmic indications

Glaucoma

Retinal diseases

Pharma Ophthalmic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharma Ophthalmic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharma Ophthalmic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharma Ophthalmic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pharma Ophthalmic market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pharma Ophthalmic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pharma Ophthalmic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pharma Ophthalmic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pharma Ophthalmic Industry Trends Table 2. Pharma Ophthalmic Industry Drivers Table 3. Pharma Ophthalmic Industry Opportunities and Challenges Table 4. Pharma Ophthalmic Industry Restraints Table 5. Global Pharma Ophthalmic Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pharma Ophthalmic Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pharma Ophthalmic Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Pharma Ophthalmic Sales Market Share by Manufacturers Table 9. Global Pharma Ophthalmic Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pharma Ophthalmic Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pharma Ophthalmic Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pharma Ophthalmic Manufacturers, Product Type & Application Table 13. Global Pharma Ophthalmic Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pharma Ophthalmic by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Retinal disorders drugs Table 17. Major Manufacturers of Glaucoma drugs Table 18. Major Manufacturers of Other ophthalmic drugs Table 19. Major Manufacturers of Allergic, inflammatory and infective drugs Table 20. Major Manufacturers of Dry eye drugs Table 21. Global Pharma Ophthalmic Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Pharma Ophthalmic Sales by Type (2021-2026) & (W Units) Table 23. Global Pharma Ophthalmic Sales by Type (2027-2032) & (W Units) Table 24. Global Pharma Ophthalmic Sales Market Share by Type (2021-2026) Table 25. Global Pharma Ophthalmic Sales Market Share by Type (2027-2032) Table 26. Global Pharma Ophthalmic Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Pharma Ophthalmic Revenue by Type (2021-2026) & (W Units) Table 28. Global Pharma Ophthalmic Revenue by Type (2027-2032) & (W Units) Table 29. Global Pharma Ophthalmic Revenue Market Share by Type (2021-2026) Table 30. Global Pharma Ophthalmic Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Dry eye syndrome Table 32. Major Manufacturers of Other ophthalmic indications Table 33. Major Manufacturers of Glaucoma Table 34. Major Manufacturers of Retinal diseases Table 35. Global Pharma Ophthalmic Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Pharma Ophthalmic Sales by Application (2021-2026) & (W Units) Table 37. Global Pharma Ophthalmic Sales by Application (2027-2032) & (W Units) Table 38. Global Pharma Ophthalmic Sales Market Share by Application (2021-2026) Table 39. Global Pharma Ophthalmic Sales Market Share by Application (2027-2032) Table 40. Global Pharma Ophthalmic Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Pharma Ophthalmic Revenue by Application (2021-2026) & (W Units) Table 42. Global Pharma Ophthalmic Revenue by Application (2027-2032) & (W Units) Table 43. Global Pharma Ophthalmic Revenue Market Share by Application (2021-2026) Table 44. Global Pharma Ophthalmic Revenue Market Share by Application (2027-2032) Table 45. Global Pharma Ophthalmic Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Pharma Ophthalmic Sales by Region (2021-2026) & (W Units) Table 47. Global Pharma Ophthalmic Sales Market Share by Region (2021-2026) Table 48. Global Pharma Ophthalmic Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Pharma Ophthalmic Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Pharma Ophthalmic Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Pharma Ophthalmic Sales by Country (2021-2026) & (W Units) Table 52. North America Pharma Ophthalmic Sales by Country (2027-2032) & (W Units) Table 53. Europe Pharma Ophthalmic Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Pharma Ophthalmic Sales by Country (2021-2026) & (W Units) Table 55. Europe Pharma Ophthalmic Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Pharma Ophthalmic Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Pharma Ophthalmic Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Pharma Ophthalmic Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Pharma Ophthalmic Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Pharma Ophthalmic Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Pharma Ophthalmic Sales by Country (2027-2032) & (W Units) Table 62. Global Pharma Ophthalmic Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Pharma Ophthalmic Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Pharma Ophthalmic Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Pharma Ophthalmic Revenue Market Share by Region (2021-2026) Table 66. Global Pharma Ophthalmic Revenue Market Share by Region (2027-2032) Table 67. Akorn Company Information Table 68. Akorn Business Overview Table 69. Akorn Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Akorn Pharma Ophthalmic Product Portfolio Table 71. Akorn Recent Development Table 72. Allergan Company Information Table 73. Allergan Business Overview Table 74. Allergan Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Allergan Pharma Ophthalmic Product Portfolio Table 76. Allergan Recent Development Table 77. Regeneron Company Information Table 78. Regeneron Business Overview Table 79. Regeneron Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Regeneron Pharma Ophthalmic Product Portfolio Table 81. Regeneron Recent Development Table 82. Senju Company Information Table 83. Senju Business Overview Table 84. Senju Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Senju Pharma Ophthalmic Product Portfolio Table 86. Senju Recent Development Table 87. Valeant Company Information Table 88. Valeant Business Overview Table 89. Valeant Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Valeant Pharma Ophthalmic Product Portfolio Table 91. Valeant Recent Development Table 92. Bayer Company Information Table 93. Bayer Business Overview Table 94. Bayer Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Bayer Pharma Ophthalmic Product Portfolio Table 96. Bayer Recent Development Table 97. Santen Company Information Table 98. Santen Business Overview Table 99. Santen Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Santen Pharma Ophthalmic Product Portfolio Table 101. Santen Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Pfizer Pharma Ophthalmic Product Portfolio Table 106. Pfizer Recent Development Table 107. Roche Company Information Table 108. Roche Business Overview Table 109. Roche Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Roche Pharma Ophthalmic Product Portfolio Table 111. Roche Recent Development Table 112. Novartis Company Information Table 113. Novartis Business Overview Table 114. Novartis Pharma Ophthalmic Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Novartis Pharma Ophthalmic Product Portfolio Table 116. Novartis Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Pharma Ophthalmic Distributors List Table 120. Pharma Ophthalmic Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Pharma Ophthalmic Product Image Figure 2. Global Pharma Ophthalmic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharma Ophthalmic Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharma Ophthalmic Sales (2021-2032) & (W Units) Figure 5. Global Pharma Ophthalmic Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pharma Ophthalmic Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Retinal disorders drugs Image Figure 9. Glaucoma drugs Image Figure 10. Other ophthalmic drugs Image Figure 11. Allergic, inflammatory and infective drugs Image Figure 12. Dry eye drugs Image Figure 13. Global Pharma Ophthalmic Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Pharma Ophthalmic Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Pharma Ophthalmic Sales Market Share by Type (2021-2032) Figure 16. Global Pharma Ophthalmic Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Pharma Ophthalmic Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Pharma Ophthalmic Revenue Market Share by Type (2021-2032) Figure 19. Dry eye syndrome Image Figure 20. Other ophthalmic indications Image Figure 21. Glaucoma Image Figure 22. Retinal diseases Image Figure 23. Global Pharma Ophthalmic Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Pharma Ophthalmic Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Pharma Ophthalmic Sales Market Share by Application (2021-2032) Figure 26. Global Pharma Ophthalmic Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Pharma Ophthalmic Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Pharma Ophthalmic Revenue Market Share by Application (2021-2032) Figure 29. North America Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Pharma Ophthalmic Sales Market Share by Country (2021-2032) Figure 31. U.S. Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Pharma Ophthalmic Sales Market Share by Country (2021-2032) Figure 36. Germany Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Pharma Ophthalmic Sales Market Share by Country (2021-2032) Figure 43. China Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Pharma Ophthalmic Sales Market Share by Country (2021-2032) Figure 51. Brazil Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Pharma Ophthalmic Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Pharma Ophthalmic Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Pharma Ophthalmic Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Pharma Ophthalmic Revenue (2021-2032) & (US$ Million) Figure 62. North America Pharma Ophthalmic Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Pharma Ophthalmic Revenue (2021-2032) & (US$ Million) Figure 64. Europe Pharma Ophthalmic Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Pharma Ophthalmic Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Pharma Ophthalmic Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Pharma Ophthalmic Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Pharma Ophthalmic Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Pharma Ophthalmic Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Pharma Ophthalmic Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Retinal disorders drugs
  • Glaucoma drugs
  • Other ophthalmic drugs
  • Allergic, inflammatory and infective drugs
  • Dry eye drugs
Applications
  • Dry eye syndrome
  • Other ophthalmic indications
  • Glaucoma
  • Retinal diseases
Companies covered
  • Akorn
  • Allergan
  • Regeneron
  • Senju
  • Valeant
  • Bayer
  • Santen
  • Pfizer
  • Roche
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharma Ophthalmic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharma Ophthalmic Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pharma Ophthalmic Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pharma Ophthalmic Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pharma Ophthalmic Market Dynamics
  1. 2.1 Pharma Ophthalmic Industry Trends
  2. 2.2 Pharma Ophthalmic Industry Drivers
  3. 2.3 Pharma Ophthalmic Industry Opportunities and Challenges
  4. 2.4 Pharma Ophthalmic Industry Restraints
3 Pharma Ophthalmic Market by Manufacturers
  1. 3.1 Global Pharma Ophthalmic Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pharma Ophthalmic Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pharma Ophthalmic Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pharma Ophthalmic Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pharma Ophthalmic Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pharma Ophthalmic Manufacturers, Product Type & Application
  7. 3.7 Global Pharma Ophthalmic Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pharma Ophthalmic Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pharma Ophthalmic Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pharma Ophthalmic Tier 1, Tier 2, and Tier 3
4 Pharma Ophthalmic Market by Type
  1. 4.1 Pharma Ophthalmic Type Introduction
  2. 4.1.1 Retinal disorders drugs
  3. 4.1.2 Glaucoma drugs
  4. 4.1.3 Other ophthalmic drugs
  5. 4.1.4 Allergic, inflammatory and infective drugs
  6. 4.1.5 Dry eye drugs
  7. 4.2 Global Pharma Ophthalmic Sales by Type
  8. 4.2.1 Global Pharma Ophthalmic Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pharma Ophthalmic Sales by Type (2021-2032)
  10. 4.2.3 Global Pharma Ophthalmic Sales Market Share by Type (2021-2032)
  11. 4.3 Global Pharma Ophthalmic Revenue by Type
  12. 4.3.1 Global Pharma Ophthalmic Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Pharma Ophthalmic Revenue by Type (2021-2032)
  14. 4.3.3 Global Pharma Ophthalmic Revenue Market Share by Type (2021-2032)
5 Pharma Ophthalmic Market by Application
  1. 5.1 Pharma Ophthalmic Application Introduction
  2. 5.1.1 Dry eye syndrome
  3. 5.1.2 Other ophthalmic indications
  4. 5.1.3 Glaucoma
  5. 5.1.4 Retinal diseases
  6. 5.2 Global Pharma Ophthalmic Sales by Application
  7. 5.2.1 Global Pharma Ophthalmic Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Pharma Ophthalmic Sales by Application (2021-2032)
  9. 5.2.3 Global Pharma Ophthalmic Sales Market Share by Application (2021-2032)
  10. 5.3 Global Pharma Ophthalmic Revenue by Application
  11. 5.3.1 Global Pharma Ophthalmic Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Pharma Ophthalmic Revenue by Application (2021-2032)
  13. 5.3.3 Global Pharma Ophthalmic Revenue Market Share by Application (2021-2032)
6 Global Pharma Ophthalmic Sales by Region
  1. 6.1 Global Pharma Ophthalmic Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharma Ophthalmic Sales by Region (2021-2032)
  3. 6.2.1 Global Pharma Ophthalmic Sales by Region (2021-2026)
  4. 6.2.2 Global Pharma Ophthalmic Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharma Ophthalmic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pharma Ophthalmic Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pharma Ophthalmic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pharma Ophthalmic Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pharma Ophthalmic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pharma Ophthalmic Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pharma Ophthalmic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pharma Ophthalmic Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pharma Ophthalmic Revenue by Region
  1. 7.1 Global Pharma Ophthalmic Revenue by Region
  2. 7.1.1 Global Pharma Ophthalmic Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pharma Ophthalmic Revenue by Region (2021-2026)
  4. 7.1.3 Global Pharma Ophthalmic Revenue by Region (2027-2032)
  5. 7.1.4 Global Pharma Ophthalmic Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pharma Ophthalmic Revenue (2021-2032)
  8. 7.2.2 North America Pharma Ophthalmic Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pharma Ophthalmic Revenue (2021-2032)
  11. 7.3.2 Europe Pharma Ophthalmic Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pharma Ophthalmic Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pharma Ophthalmic Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pharma Ophthalmic Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pharma Ophthalmic Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Akorn
  2. 8.1.1 Akorn Company Information
  3. 8.1.2 Akorn Business Overview
  4. 8.1.3 Akorn Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Akorn Pharma Ophthalmic Product Portfolio
  6. 8.1.5 Akorn Recent Developments
  7. 8.2 Allergan
  8. 8.2.1 Allergan Company Information
  9. 8.2.2 Allergan Business Overview
  10. 8.2.3 Allergan Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Allergan Pharma Ophthalmic Product Portfolio
  12. 8.2.5 Allergan Recent Developments
  13. 8.3 Regeneron
  14. 8.3.1 Regeneron Company Information
  15. 8.3.2 Regeneron Business Overview
  16. 8.3.3 Regeneron Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Regeneron Pharma Ophthalmic Product Portfolio
  18. 8.3.5 Regeneron Recent Developments
  19. 8.4 Senju
  20. 8.4.1 Senju Company Information
  21. 8.4.2 Senju Business Overview
  22. 8.4.3 Senju Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Senju Pharma Ophthalmic Product Portfolio
  24. 8.4.5 Senju Recent Developments
  25. 8.5 Valeant
  26. 8.5.1 Valeant Company Information
  27. 8.5.2 Valeant Business Overview
  28. 8.5.3 Valeant Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Valeant Pharma Ophthalmic Product Portfolio
  30. 8.5.5 Valeant Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Pharma Ophthalmic Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Santen
  38. 8.7.1 Santen Company Information
  39. 8.7.2 Santen Business Overview
  40. 8.7.3 Santen Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Santen Pharma Ophthalmic Product Portfolio
  42. 8.7.5 Santen Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Pharma Ophthalmic Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Pharma Ophthalmic Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Pharma Ophthalmic Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Pharma Ophthalmic Product Portfolio
  60. 8.10.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pharma Ophthalmic Value Chain Analysis
  2. 9.1.1 Pharma Ophthalmic Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pharma Ophthalmic Production Mode & Process
  6. 9.2 Pharma Ophthalmic Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pharma Ophthalmic Distributors
  9. 9.2.3 Pharma Ophthalmic Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst